Free Trial

CNS Pharmaceuticals Q4 2023 Earnings Report

CNS Pharmaceuticals logo
$1.10 -0.03 (-2.65%)
As of 04:00 PM Eastern

CNS Pharmaceuticals EPS Results

Actual EPS
-$2,375.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CNS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CNS Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

CNS Pharmaceuticals Earnings Headlines

CNS Pharmaceuticals sees cash runway into 1Q26
Forget 99% of the entire stock market. Trade this one stock instead
Jeff Clark says he joined the top 1% of wealthy Americans by doing something radically simple — ignoring 99% of the stock market and trading just one specific gold stock. He calls it the “One Gold Stock Retirement” strategy. Through bull and bear markets alike, he’s used this same trade to rack up triple-digit gains — often outperforming gold itself. And he's not the only one: over 20,000 everyday investors have tapped into this approach to pursue financial freedom. Whether you’re starting with $100 or $1 million, this monthly trade could help you profit in any market — even during crashes.
CNS Pharmaceuticals announces primary analysis of berubicin in GBM
See More CNS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email.

About CNS Pharmaceuticals

CNS Pharmaceuticals (NASDAQ:CNSP), a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

View CNS Pharmaceuticals Profile

More Earnings Resources from MarketBeat